Wanted: New drug developers for empty R&D complex

Sanofi's ($SNY) decision to pull its R&D operations out of Bridgewater, NJ, and relocate to Boston has left a 1.2 million-square-foot problem for state and local economic development officials to deal with. Sanofi completed the move ahead of schedule as it pushes ahead with plans to downsize its research operations in France, reports the Star-Ledger. The state biotech group would like to see up-and-coming biotechs move into the vacated, 20-building research complex. Local officials would probably be satisfied with new tenants of all stripes. Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.